Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT07445386

Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain

Led by Ankara Etlik City Hospital · Updated on 2026-03-03

56

Participants Needed

1

Research Sites

30 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to compare the efficacy of fluoroscopy-guided paravertebral (PV) and transdiscal (TD) approaches for splanchnic nerve neurolysis in patients with upper abdominal cancer-related pain (e.g., gastric, pancreatic, and hepatic malignancies). Treatment response will be assessed using the Numerical Rating Scale (NRS), and the impact of both techniques on quality of life will be evaluated with the EORTC QLQ-C30 questionnaire.

CONDITIONS

Official Title

Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Severe abdominal pain (NRS > 6) due to upper intra-abdominal organ malignancies such as gastric, pancreatic, or hepatic cancer
  • Pain not controlled by conservative treatment methods
Not Eligible

You will not qualify if you...

  • Presence of local anatomical variations
  • Localized or systemic infection involving the procedural site
  • Pregnancy
  • Coagulopathy
  • Unstable psychiatric disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ankara Etlik City Hospital

Ankara, Turkey (Türkiye)

Actively Recruiting

Loading map...

Research Team

G

Gokhan Yildiz

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here